Paclitaxel for Breast Cancer: 167 Real Stories

167 stories match breast cancer and paclitaxel. 151 of them mention surgery.

Nathalie, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Nathalie's Patient Story

Patient Info: Nathalie | Stage IV

Nathalie had been living with stage 4 breast cancer for more than three years and remained focused on time with her children.

Our Cancer Stories
OutcomeLiving With Cancer
Kevin, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I Breast Cancer: Kevin's Patient Story

Patient Info: Kevin Jarvis, Male | Stage I

Biomarkers: Genetic testing inconclusive; receptor status not reported

Early male breast cancer treated with mastectomy, sentinel node biopsy, EC chemotherapy, paclitaxel/Taxol, and ongoing daily tamoxifen; latest source text describes good spirits and continued discussion of risk-reducing surgery, but does not explicitly state NED.

Cancer Council Australia
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

How Learning To Ask For Help Can Make Life With MBC Easier

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Not explicitly reported; HER2-targeted treatment with Herceptin and Tykerb reported

Metastatic Site: Brain; liver

Living with Stage IV metastatic breast cancer involving brain and liver; latest scans showed no evidence of disease, and she reported spending most of her Stage IV life in NED status.

breastcancer.org
OutcomeCancer-Free / NED
Genevieve, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Genevieve's Survivor Story

Patient Info: Genevieve, Female, 40s

Biomarkers: 1987 tumor not hormone-receptive; 2017 tumor hormone-receptive. 2022 full marker panel not stated.

After breast cancer episodes beginning in 1987, another tumor in 2017, and cancer found again in 2022, PET scans every 3-4 months were clear and she described herself as in remission again as of May 2025.

breastcancer.org
OutcomeCancer-Free / NED
Cher, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Cher's Survivor Story

Patient Info: Cher, Female | Stage III

Biomarkers: Hormone-positive; HER2-negative; Oncotype DX score 0

No evidence of disease after treatment for Stage IIIB breast cancer, with ongoing adjuvant Verzenio, long-term hormone blockers, and planned preventive mastectomy/DIEP flap reconstruction.

breastcancer.org
OutcomeCancer-Free / NED
Michelle, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I Breast Cancer: Michelle's Survivor Story

Patient Info: Michelle Kang, Female, Under 40 | Stage I

Biomarkers: Hormone-positive breast cancer; no suspicious inherited genetic mutation reported

Michelle was 6 years cancer-free after Stage 1B hormone-positive breast cancer while continuing hormone therapy, Zometa, Signatera blood testing, reconstruction follow-up, and survivorship monitoring.

City of Hope
OutcomeCancer-Free / NED
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Stefanie, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient Story
OutcomeTreatment Completed / Survivorship
Lucy, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient Story
OutcomeCancer-Free / NED, Surveillance
Melissa, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Melissa's Survivor Story

Patient Info: Melissa, Female | Stage II

Biomarkers: Triple-negative breast cancer; BRCA testing negative; NBN gene mutation identified on later testing

Melissa completed pregnancy-adapted cancer treatment, later underwent risk-reducing surgery and reconstruction, and was raising both daughters.

The Patient Story
OutcomeTreatment Completed / Survivorship
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed Central
OutcomeCancer-Free / NED
Bethany, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient Story
OutcomeCare Ongoing
Stephanie, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient Story
OutcomeCancer-Free / NED
Callie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Andrea, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Andrea's Survivor Story

Patient Info: Andrea, Female, Under 40 | Stage III

Completed chemotherapy, mastectomy/reconstruction, and radiation for Stage IIB-to-Stage III breast cancer diagnosed during pregnancy, and later described survivorship, parenting, fatigue, relationship strain, and recovery after treatment.

The Patient Story
OutcomeSurvivorship / Surveillance
Erin, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient Story
OutcomeResponding Well
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
Margaret, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II Invasive Ductal Carcinoma: Margaret's Survivor Story

Patient Info: Margaret, Female | Stage II

Biomarkers: Onco-typing score 18; hormone-responsive tumor described; exact receptor status not reported

As of June 2026, Margaret’s story described completed surgery, chemotherapy, radiation, and later reconstruction for Stage II IDC/DCIS breast cancer, with survivorship focused on recovery, neuropathy, and integrative support rather than an explicit NED claim.

The Patient Story
OutcomeSurvivorship / Surveillance
Monica, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Renee, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed Central
OutcomeResponding Well
SI
Breast Cancer

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.

Susan G. Komen
OutcomeCare Ongoing
Marina, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female | Stage II

Stage II breast cancer survivor after chemotherapy, with ongoing survivorship advice focused on hair loss, neuropathy, fertility preservation, nausea, fatigue, chemo brain, and support.

The Patient Story
OutcomeSurvivorship / Completed Treatment